Advancements in Alzheimer’s Disease Treatment: Exploring Novel Approaches and Strategies

Dear Colleagues,

Alzheimer’s disease (AD) and related neurodegenerative disorders pose a significant challenge to global health, with an increasing burden on patients, caregivers, and healthcare systems. Despite extensive research, effective treatments and preventive measures for these diseases remain elusive. To address this pressing issue, we invite researchers to submit manuscripts that explore innovative approaches and novel treatment strategies for AD and other related neurodegenerative diseases. We particularly encourage bioinformatics studies which are validated via in vitro and in vivo experiments. We also included traditional preclinical and clinical treatment studies with novel compounds.

We seek submissions that focus on cutting-edge bioinformatics-based research to identify potential pharmacological targets and biomarkers for early detection and intervention. Manuscripts may include, but are not limited to, the following topics:

1. Computational methods for drug discovery in AD and related neurodegenerative diseases, such as Parkinson’s diseases, demyelinating diseases, prion diseases, post-ischemic brain neurodegeneration, Alzheimer’s disease models, and more.
2. The identification of novel genetic, epigenetic, and proteomic biomarkers for early diagnosis and prognosis.
3. Systems biology approaches, unraveling the complex pathophysiology of neurodegenerative disorders.
4. Machine learning and artificial intelligence techniques for analyzing large-scale omics data related to AD and other related neurodegenerative diseases.
5. Translational bioinformatics studies that bridge the gap between basic research and clinical applications in AD and other related neurodegenerative diseases.

Through uniting diverse perspectives and methodologies, we will catalyze the development of new strategies for preventing, diagnosing, and treating AD and other related neurodegenerative diseases. The integration of bioinformatics-based approaches with traditional research methods will be pivotal in advancing our understanding of these complex disorders, ultimately contributing to AD prevention and progression.

Dr. Sunmin Park
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• bioinformatics
• novel compounds
• in vitro
• in vivo
• clinical study
• Alzheimer’s disease models